IGFBP-3 Blocks Hyaluronan-CD44 Signaling, Leading to Increased Acetylcholinesterase Levels in A549 Cell Media and Apoptosis in a p53-Dependent Manner

[1]  S. Rosenzweig.  Faculty Opinions recommendation of IGF-Binding Proteins: Why Do They Exist and Why Are There So Many? , 2020 .

[2]  E. Turley,et al.  Dissecting the Dual Nature of Hyaluronan in the Tumor Microenvironment , 2019, Front. Immunol..

[3]  M. Bulyk,et al.  The multiple mechanisms that regulate p53 activity and cell fate , 2019, Nature Reviews Molecular Cell Biology.

[4]  P. Dasgupta,et al.  Acetylcholine signaling system in progression of lung cancers , 2019, Pharmacology & therapeutics.

[5]  J. Guthrie,et al.  Interaction of Insulin-Like Growth Factor-Binding Protein 3 With Hyaluronan and Its Regulation by Humanin and CD44. , 2018, Biochemistry.

[6]  J. Zucman‐Rossi,et al.  Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. , 2018, Cancer cell.

[7]  C. Chen,et al.  The biology and role of CD44 in cancer progression: therapeutic implications , 2018, Journal of Hematology & Oncology.

[8]  C. Duan,et al.  IGF-Binding Proteins: Why Do They Exist and Why Are There So Many? , 2018, Front. Endocrinol..

[9]  A. Strasser,et al.  How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? , 2018 .

[10]  V. Vasić,et al.  Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs. , 2017, Current medicinal chemistry.

[11]  R. Newman,et al.  D-Amino Acid Analogues of the Antimicrobial Peptide CDT Exhibit Anti- Cancer Properties in A549, a Human Lung Adenocarcinoma Cell Line. , 2017, Protein Peptide Letters.

[12]  A. Dicker,et al.  IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling , 2017, Molecular Cancer Research.

[13]  Ameya R. Kirtane,et al.  Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling , 2017, Oncotarget.

[14]  Mimi Y. Kim,et al.  Associations of Insulin and IGFBP-3 with Lung Cancer Susceptibility in Current Smokers. , 2016, Journal of the National Cancer Institute.

[15]  Dragana Nikitovic,et al.  Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer. , 2016, Current drug delivery.

[16]  N. Altorki,et al.  Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma , 2016, Oncotarget.

[17]  S. Tavaré,et al.  Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target , 2015, Journal of the National Cancer Institute.

[18]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[19]  M. Jaafari,et al.  Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[20]  D. Heyl,et al.  Humanin Peptide Binds to Insulin-Like Growth Factor-Binding Protein 3 (IGFBP3) and Regulates Its Interaction with Importin-β. , 2015, Protein and peptide letters.

[21]  M. Amiji,et al.  Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine* , 2015, Journal of drug targeting.

[22]  S. Garantziotis,et al.  Size Matters: Molecular Weight Specificity of Hyaluronan Effects in Cell Biology , 2015, International journal of cell biology.

[23]  S. Back,et al.  Hyaluronan Synthesis, Catabolism, and Signaling in Neurodegenerative Diseases , 2015, International journal of cell biology.

[24]  K. Kimata,et al.  Key Roles of Hyaluronan and Its CD44 Receptor in the Stemness and Survival of Cancer Stem Cells , 2015, Front. Oncol..

[25]  R. Baxter,et al.  Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer , 2015, BioMed research international.

[26]  Baocun Sun,et al.  Transforming growth factor-β1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cells , 2015, International journal of molecular medicine.

[27]  G. Wilczynski,et al.  CD44: molecular interactions, signaling and functions in the nervous system , 2015, Front. Cell. Neurosci..

[28]  R. Markwald,et al.  Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer , 2015, Front. Immunol..

[29]  J. Bollyky,et al.  4-Methylumbelliferone Treatment and Hyaluronan Inhibition as a Therapeutic Strategy in Inflammation, Autoimmunity, and Cancer , 2015, Front. Immunol..

[30]  Zhaoshen Li,et al.  Role of acetylcholinesterase in lung cancer , 2015, Thoracic cancer.

[31]  Changsong Zhang,et al.  Upregulation of Acetylcholinesterase Mediated by p53 Contributes to Cisplatin-Induced Apoptosis in Human Breast Cancer Cell , 2015, Journal of Cancer.

[32]  Jing Wang,et al.  Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance , 2014, Genes & diseases.

[33]  Yeonho Choi,et al.  Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44 , 2014, Experimental lung research.

[34]  D. Vigetti,et al.  Hyaluronan: biosynthesis and signaling. , 2014, Biochimica et biophysica acta.

[35]  J. Minna,et al.  Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment , 2014, Human mutation.

[36]  R. Baxter,et al.  IGF binding proteins in cancer: mechanistic and clinical insights , 2014, Nature Reviews Cancer.

[37]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[38]  Jun Wu,et al.  Synaptic acetylcholinesterase targeted by microRNA-212 functions as a tumor suppressor in non-small cell lung cancer. , 2013, The international journal of biochemistry & cell biology.

[39]  P. Sharp,et al.  CD44 promotes Kras-dependent lung adenocarcinoma , 2013, Oncogene.

[40]  E. Raso,et al.  Demonstration of a Melanoma-Specific CD44 Alternative Splicing Pattern That Remains Qualitatively Stable, but Shows Quantitative Changes during Tumour Progression , 2013, PloS one.

[41]  P. Dasgupta,et al.  Measurement of Acetylcholine from Cell Lines. , 2013, Bio-protocol.

[42]  D. Diaz,et al.  Protein-Carbohydrate Interactions Studied by NMR: From Molecular Recognition to Drug Design , 2012, Current protein & peptide science.

[43]  V. Morsch,et al.  Ectoenzymes and cholinesterase activity and biomarkers of oxidative stress in patients with lung cancer , 2012, Molecular and Cellular Biochemistry.

[44]  H. Shepard,et al.  Therapeutic Targeting of Hyaluronan in the Tumor Stroma , 2012, Cancers.

[45]  K. Konstantopoulos,et al.  Distinct kinetic and molecular requirements govern CD44 binding to hyaluronan versus fibrin(ogen). , 2012, Biophysical journal.

[46]  D. Greenberg,et al.  Acetylcholinesterase Involvement in Apoptosis , 2012, Front. Mol. Neurosci..

[47]  R. Norton,et al.  Insulin-Like Growth Factor Binding Proteins: A Structural Perspective , 2012, Front. Endocrin..

[48]  P. Park,et al.  Shedding of cell membrane-bound proteoglycans. , 2012, Methods in molecular biology.

[49]  R. Markwald,et al.  Hyaluronan–CD44 interactions as potential targets for cancer therapy , 2011, The FEBS journal.

[50]  B. Toole.  Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities , 2009, Clinical Cancer Research.

[51]  S. Bustin,et al.  The expression and function of IGFBP-3 in normal and malignant breast tissue. , 2009, Anticancer research.

[52]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[53]  D. Feldman,et al.  Unraveling insulin-like growth factor binding protein-3 actions in human disease. , 2009, Endocrine reviews.

[54]  M. Shojaie,et al.  Annexin V and anti-Annexin V antibodies: two interesting aspects in acute myocardial infarction , 2009, Thrombosis journal.

[55]  M. Kearney,et al.  IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis , 2009, Trends in Endocrinology & Metabolism.

[56]  J. N. Rodríguez-López,et al.  Cancer-associated differences in acetylcholinesterase activity in bronchial aspirates from patients with lung cancer. , 2008, Clinical science.

[57]  R. Weinberg,et al.  Growth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 Expression , 2008, Cell.

[58]  H. Sekhon,et al.  Activated cholinergic signaling provides a target in squamous cell lung carcinoma. , 2008, Cancer research.

[59]  M. Slomiany,et al.  Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[60]  F. Ruíz-Espejo,et al.  05) Acetylcholinesterase biogenesis is impaired in lung cancer tissues , 2005 .

[61]  R. Norton,et al.  IGF-binding proteins – the pieces are falling into place , 2005, Trends in Endocrinology & Metabolism.

[62]  F. Ruíz-Espejo,et al.  Acetylcholinesterase biogenesis is impaired in lung cancer tissues. , 2005, Chemico-Biological Interactions.

[63]  Lin Ji,et al.  Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. , 2004, Journal of the National Cancer Institute.

[64]  M. Dohadwala,et al.  Cyclooxygenase-2 Modulates the Insulin-Like Growth Factor Axis in Non–Small-Cell Lung Cancer , 2004, Cancer Research.

[65]  B. Toole,et al.  Hyaluronan: from extracellular glue to pericellular cue , 2004, Nature Reviews Cancer.

[66]  F. Campoy,et al.  Cholinesterase Activity and Acetylcholinesterase Glycosylation are Altered in Human Breast Cancer , 2002, Breast Cancer Research and Treatment.

[67]  A. Williams,et al.  IGFBP-3 and apoptosis—a licence to kill? , 2001, Apoptosis.

[68]  Li Mao,et al.  Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  R. Baxter,et al.  Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.

[70]  W. El-Deiry,et al.  IGFBP-3 mediates p53-induced apoptosis during serum starvation. , 2002, International journal of oncology.

[71]  K. Mikecz,et al.  Hyaluronan Binding Properties of a CD44 Chimera Containing the Link Module of TSG-6* , 2002, The Journal of Biological Chemistry.

[72]  Pinchas Cohen,et al.  Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. , 2002, Cancer research.

[73]  Lei Yang,et al.  Induction of acetylcholinesterase expression during apoptosis in various cell types , 2002, Cell Death and Differentiation.

[74]  J. Clifford,et al.  Direct Functional Interactions between Insulin-like Growth Factor-binding Protein-3 and Retinoid X Receptor-α Regulate Transcriptional Signaling and Apoptosis* , 2000, The Journal of Biological Chemistry.

[75]  S. Kohno,et al.  Expression of CD44 Variants in Lung Cancer and Its Relationship to Hyaluronan Binding , 2000, The Journal of international medical research.

[76]  D. Jackson,et al.  Characterization of a functional hyaluronan-binding domain from the human CD44 molecule expressed in Escherichia coli. , 1998, Protein expression and purification.

[77]  J. Bajorath,et al.  Identification of CD44 Residues Important for Hyaluronan Binding and Delineation of the Binding Site* , 1998, The Journal of Biological Chemistry.

[78]  J. Fowlkes,et al.  Heparin-binding, highly basic regions within the thyroglobulin type-1 repeat of insulin-like growth factor (IGF)-binding proteins (IGFBPs) -3, -5, and -6 inhibit IGFBP-4 degradation. , 1997, Endocrinology.

[79]  P. Cohen,et al.  Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent Mechanism* , 1997, The Journal of Biological Chemistry.

[80]  J. Fowlkes,et al.  Characterization of Glycosaminoglycan-binding Domains Present in Insulin-like Growth Factor-binding Protein-3* , 1996, The Journal of Biological Chemistry.

[81]  D. Small,et al.  Non-classical actions of cholinesterases: Role in cellular differentiation, tumorigenesis and Alzheimer's disease , 1996, Neurochemistry International.

[82]  R. Baxter,et al.  Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. , 1995, Endocrinology.

[83]  J. Weiler,et al.  IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. , 1995, Growth regulation.

[84]  P. Singer.  Licence to kill , 1994, Nature.

[85]  R. Savani,et al.  Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. , 1994, The EMBO journal.

[86]  I. Stamenkovic,et al.  CD44 is the principal cell surface receptor for hyaluronate , 1990, Cell.

[87]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.